News
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jul 23, 2020Intratracheal administration of exosomes extracted from MSC’s using NurOwn® technology resulted in statistically significant improvement in multiple lung parameters in a mouse modelBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has successfully completed its first...
-
Jul 8, 2020Recently announced expansion of NurOwn® development program, adding Alzheimer's disease
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion Leader (KOL) webinar on its Alzheimer's...
-
Jul 2, 2020Topline data expected in 4Q 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that final participant dosing has been...
-
Jul 1, 2020Lead investigators to discuss BrainStorm's newly announced Phase 2 trial Alzheimer's disease on July 8, 2020 at 8.15 AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, will hold a Key Opinion Leader (KOL) webinar on the Company's...
-
Jun 24, 2020Protocol for the proposed multi-national trial has been submitted for EU regulatory approval
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced a new clinical program focused on the development...
-
Jun 23, 2020
BrainStorm Cell Therapeutics Inc. (NasdaqCM: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that its shares will join the Russell 2000®...
-
Jun 15, 2020
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
-
Jun 11, 2020Management to Host One-on-One Investment Meetings
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc,...
Jun 9, 2020Research Study to Use Data and Samples from NurOwn® Phase 3 Clinical TrialThe ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASDAQ: BCLI), a biotechnology company, to...
- Jun 3, 2020Management to Host One-on-One Partnering Meetings
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Dr. Ralph Kern, M.D, President and Chief Medical...
- Jun 2, 2020The fully enrolled placebo-controlled Phase 3 trial is evaluating NurOwn® investigational treatment in ALS patients
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today an update on the Company's Phase 3 pivotal trial...
- May 27, 2020Experience Developing, Seeking Regulatory Approval of and Commercializing Multi-Billion Dollar Neurology Therapies
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Stacy R. Lindborg, Ph.D. has been appointed...
- May 7, 2020BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate UpdateConference Call and Webcast Today at 8:30 a.m. Eastern Time
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial...
- May 4, 2020
NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced...
- Apr 29, 2020Thursday, May 7, 2020, 8:30 a.m. EDT
NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Apr 3, 2020
NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
- Apr 1, 2020International Pharmaceutical Veteran to Lead Global Business and Commercial Development
NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that David...
- Mar 31, 2020Prof. Frenkel, Chairman of the Group of Thirty (G-30) Board of Trustees, Former Chairman of JPMorgan Chase International and Former Governor of the Bank of Israel Joins the Board to Support the Company’s Global Expansion
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced the...
- Mar 16, 2020Funding Secured and Senior Management Team Activated by CEO to Ensure Advancement of all Operational Activities and Completion of Corporate Clinical Milestones
NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Mar 6, 2020
NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has...
- Feb 27, 2020
NEW YORK and BOSTON, Feb. 27, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Feb 18, 2020Conference Call and Webcast @ 8:00 a.m. Eastern Time Today
NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces...
- Feb 17, 2020
NEW YORK, Feb. 17, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative...
- Feb 11, 2020
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
- Feb 10, 2020
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
- Feb 4, 2020
NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative...
- Jan 29, 2020
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...
- Jan 21, 2020
NEW YORK and LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases,...
- Jan 7, 2020
NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today...
- Dec 19, 2019
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
- Dec 19, 2019
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the...
- Dec 18, 2019
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Letter to...
-
Dec 11, 2019
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
- Nov 26, 2019BrainStorm’s Chief Operating and Chief Medical Officer, Ralph Kern MD MHSc, will make a podium presentation at Clinical Trials Session
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
- Nov 25, 2019
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Nov 20, 2019A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to 12-16 weeks in a prespecified subgroup of ALS rapid progressors
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
- Nov 14, 2019BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate UpdateConference Call and Webcast Today at 8:00 a.m. Eastern Time
NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today...
- Nov 14, 2019
NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that...
- Nov 13, 2019
NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...
- Nov 12, 2019
NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
- Nov 5, 2019
NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
- Oct 28, 2019
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
- Oct 25, 2019
NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
- Oct 24, 2019
NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
- Oct 23, 2019
NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
- Oct 11, 2019
NEW YORK, Oct. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that...
- Oct 7, 2019
NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...
- Oct 2, 2019
NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
- Sep 27, 2019BrainStorm Holds a Roundtable Discussion with ALS Advocacy Group Leaders
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
- Sep 9, 2019
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that...
- Sep 6, 2019
NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
- Aug 13, 2019Conference Call and Webcast Today at 8:00 a.m. Eastern Time
NEW YORK, Aug. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today...
- Aug 5, 2019Tuesday, August 13, 2019, 8:00 a.m. EDT
NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Jul 2, 2019
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- May 31, 2019Design of Phase 2 Open-Label Multicenter Study in Progressive MS Outlined
NEW YORK and SEATTLE, May 31, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- May 30, 2019
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- May 28, 2019Chaim Lebovits, President & CEO Corporate Presentation, June 4, 2019 -
NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced...
- May 28, 2019
NEW YORK, NY, May 28, 2019, -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,...
- May 13, 2019BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and LONDON, May 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases,...
- May 10, 2019BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate UpdateHighlights Scientific Advances and Continued Progress in NurOwn® ALS Phase 3 Trial and Progressive MS Phase 2 Trial;
NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today...
- Apr 30, 2019
NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Brainstorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced...
- Mar 28, 2019Abstracts to highlight NurOwn® mechanism of action and correlation of Phase 2 clinical outcomes with ALS disease biomarkers
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Mar 26, 2019
NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...
- Mar 14, 2019Enrollment Announced During MS Awareness Week
NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Mar 7, 2019Tuesday, March 12th at 8.30am EDT
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Feb 22, 2019Phase 2 Open-Label Trial of Autologous MSC-NTF Cell Therapy (NurOwn®) in Progressive MS Patients will Begin Enrollment in Early 2019
NEW YORK and CLEVELAND, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Feb 21, 2019
ZURICH, Switzerland and NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly...
-
Feb 19, 2019
NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Feb 4, 2019
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Jan 25, 2019
NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Jan 22, 2019
NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative...
- Jan 11, 2019Dr. Ralph Kern to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS
NEW YORK and IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly...
- Jan 3, 2019
NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today...
- Dec 27, 2018
NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a...
- Dec 26, 2018BrainStorm has contracted with the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute, currently supporting the Phase 3 ALS Trial, to Produce NurOwn®
NEW YORK and BOSTON, Dec. 26, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases,...
- Dec 17, 2018U.S. Phase 2 Study to Begin in First Quarter of 2019
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...
- Dec 4, 2018Poster highlights enrichment strategies for clinical trials in ALS
NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...
- Nov 19, 2018
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating...
- Nov 7, 2018Highlights Preclinical Research and Continued Progress of NurOwn® Platform in ALS Pivotal Trial
NEW YORK and PETACH TIKVAH, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics...
- Oct 29, 2018BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate UpdateHighlights Scientific Advances and Continued Progress for NurOwn® in ALS Towards U.S. FDA Approval;
NEW YORK, Oct. 29, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today...
- Oct 17, 2018Conference Call and Live Webcast at 8:30am Eastern Time
NEW YORK and PETACH TIKVAH, Israel, Oct. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
- Oct 4, 2018Translational Insights Support NurOwn® as a Best-In-Class Strategy in ALS
NEW YORK and PETACH TIKVAH, Israel, Oct. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics...
- Oct 3, 2018NurOwn® to be Featured at NEALS and Cell & Gene Meeting on the Mesa Conferences
NEW YORK and PETACH TIKVAH, Israel, Oct. 03, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative adult stem cell therapeutics for...
- Sep 13, 2018
NEW YORK and PETACH TIKVAH, Israel, Sept. 13, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative...
- Sep 12, 2018
NEW YORK and PETACH TIKVAH, Israel, Sept. 12, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for debilitating...
- Sep 5, 2018Presentation and Live Webcast on Thursday, September 6th, 2.10pm ET
NEW YORK and PETACH TIKVAH, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
- Sep 4, 2018BrainStorm Appoints Arturo Araya as Chief Commercial Officer
NEW YORK and PETACH TIKVAH, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative...
- Aug 29, 2018
NEW YORK and PETACH TIKVAH, Israel, Aug. 29, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative...
- Aug 23, 2018
NEW YORK, and PETACH TIKVA, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative...
- Jul 25, 2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has...
- Jul 23, 2018Conference Call and Webcast at 8.30am ET Today
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the second quarter and...
-
Jul 17, 2018Conference Call and Live Webcast at 8.30am ET
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the second quarter ended...
-
Jul 5, 2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has received a Decision to Grant...
-
Jul 2, 2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has contracted with the Connell and...
-
Jun 28, 2018Susan Ward, Ph.D. (Pfizer) Appointed Head of Clinical Operations
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Joseph Petroziello as vice...
-
Jun 26, 2018
Webcast and Conference Call at 8:30am Eastern Time Today NEW YORK and PETACH TIKVA, Israel, June 26, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of...
-
Jun 25, 2018Conference Call and Live Webcast at 8:30am Eastern Time
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call tomorrow, June 26 th at 08:30am...
-
Jun 7, 2018
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise...
-
Jun 1, 2018Conference call and live webcast on June 7th at 8:15am EDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that the company will host a "Right-to-Try"...
-
May 30, 2018
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate...